Skip to main content
CERo Therapeutics Holdings, Inc. (CERO)
OTCMKTS · Delayed Price · Currency is USD
0.0327
+0.0020 (6.62%)
At close: Apr 29, 2026

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cost of Revenue
0.61----
Gross Profit
-0.61----
Selling, General & Admin
9.7910.733.952.840.43
Research & Development
8.685.473.72--
Other Operating Expenses
---0.060.14
Operating Expenses
19.3316.27.682.910.57
Operating Income
-19.93-16.2-7.68-2.91-0.57
Interest & Investment Income
0.010.030.142.84-
Other Non Operating Income (Expenses)
04.530.24--
EBT Excluding Unusual Items
-19.92-11.64-7.3-0.07-0.57
Gain (Loss) on Sale of Investments
-----0
Other Unusual Items
-3.340.01--
Pretax Income
-19.92-8.3-7.29-0.07-0.57
Income Tax Expense
---0.6-0.03
Net Income
-19.92-8.3-7.29-0.67-0.54
Preferred Dividends & Other Adjustments
75.612.78--36.16
Net Income to Common
-95.53-11.09-7.29-0.67-36.71
Shares Outstanding (Basic)
40-0-
Shares Outstanding (Diluted)
40-0-
Shares Change (YoY)
16477.89%----
EPS (Basic)
-22.58-434.62--59.38-
EPS (Diluted)
-22.58-434.62--59.38-
EBITDA
-19.65-15.76-7.21--
D&A For EBITDA
0.280.440.46--
EBIT
-19.93-16.2-7.68-2.91-0.57
Source: S&P Capital IQ. Standard template. Financial Sources.